Topical Calcipotriol Plus Imiquimod Immunotherapy for Nonkeratinocyte Skin Cancers
Open Access
- 11 August 2023
- journal article
- Published by Elsevier in JID Innovations
- Vol. 3 (6) , 100221
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Burroughs Wellcome Fund
- Sidney Kimmel Foundation
- LEO Pharma Research Foundation
This publication has 57 references indexed in Scilit:
- Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast CancerClinical Cancer Research, 2012
- Breast Cancer Subtypes and the Risk of Local and Regional RelapseJournal of Clinical Oncology, 2010
- The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapyImmunological Reviews, 2007
- Cutaneous infiltration by cancerJournal of the American Academy of Dermatology, 2007
- Modelling breast cancer: one size does not fit allNature Reviews Cancer, 2007
- Mammary and extramammary Paget's diseaseJournal of the European Academy of Dermatology and Venereology, 2007
- Immunosuppressive effects of 1,2 5-dihydroxyvitamin D3 and its analogue calcipotriol on epidermal cellsBritish Journal of Dermatology, 1994
- Cutaneous metastases in patients with metastatic carcinoma: A retrospective study of 4020 patientsJournal of the American Academy of Dermatology, 1993
- Extramammary Paget's diseaseClinics in Dermatology, 1993
- Topical calcipotriol treatment in advanced breast cancerThe Lancet, 1991